FDA Orange Book · active-ingredient family
Dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
Dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:EMBOLEX · NDA 018885
1
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · injectable
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| EMBOLEX×2 | NOVARTIS | NDA 018885 | — | Nov 30, 1984 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
